Comparative effectiveness of the approaches to correct vascular structural and functional disturbances in postmenopausal women

Aim. To compare the effects of Mildronate and hormone replacement therapy (HRT) with estradiol (1 mg) and drospirenone, DSPR (2 mg) on circadian blood pressure (BP) profile, arterial structure and function, and vascular stiffness parameters in women with early postmenopause and climacteric syndrome (CS).
Material and methods. The study included 94 women with early postmenopause and CS, who provided written informed consent to participate and were divided into two groups. Group I included 36 women receiving Mildronate (500 mg twice a day), while Group II included 28 women who were administered, according to clinical indications, HRT (1 mg 17β-estradiol and 2 mg DRSP once a day). The control group (CG) included 30 women who did not receive either Mildronate or DRSP. At baseline and 16 weeks later, all participants underwent the assessment of blood biochemistry; intima-media thickness (IMT) of common carotid artery (CCA); endothelium-dependent vasodilatation (EDVD) of brachial artery (BA); antithrombogenic activity of vascular wall; aortal pulse wave velocity (aPWV); arterial stiffness; and 24-hour BP monitoring (BPM).
Results. The study demonstrated positive effects of Mildronate therapy and HRT (1 mg 17β-estradiol and 2 mg DRSP) on metabolic status, circadian dynamics and variability (Var) of BP, and arterial structure and function. The largest positive changes in blood lipid profile were observed in Group I and II patients. By the end of the study, these patients demonstrated significantly decreased levels of systolic and diastolic BP and reduced BP Var, particularly in Group II. Mildronate therapy, but not HRT, was associated with normalisation of vascular wall antiaggregant potential. Group II demonstrated a significant reduction in CCA IMT levels, with a similar tendency in Group I. In both groups, the degree of endothelial dysfunction (ED) decreased, which was manifested in increased BA EDVD, decreased aPWV, and reduced arterial stiffness and was more pronounced in Group II.
Conclusion. In menopausal women with CS, the effects of Mildronate and HRT on metabolic, structural, and functional disturbances were similar. Therefore, Mildronate therapy could be a new method of correction of these systemic disturbances.

1. Atsma F, Bartelink MLEL, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265-79.

2. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976; 85(4):447-52.

3. Smetnik VP, Shestakova IG. Menopause and cardiovascular system. Ter Arkh 1999; 71(10): 61-5. Russian (Сметник В.П., Шестакова И.Г. Менопауза и сердечно-сосудистая система. Тер архив 1999; 71(10): 61-5).

4. Stevenson JQ, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.

5. Mendelsohn M, Karas R. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.

6. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-77.

7. Carr M. The emergence of metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404-11.

8. Mychka VB, Tolstov SN. Metabolic (cytoprotective) therapy of menopausal disturbances. Cardiovascular Therapy and Prevention 2011;10(3):72-76. Russian (Мычка В.Б., Толстов С.Н. Метаболическая (цитопротективная) терапия менопаузальных расстройств. Кардиоваскулярая терапия и профилактика 2011; 10(3) :72-6).

9. Salov IA, Tolstov SN, Mychka VB, et al. Menopausal metabolic syndrome and hormone replacement therapy. Obstetrics and Gynecology 2011; 2:24-31. Russian (Салов И.А., Толстов С.Н., Мычка В.Б. и др. Менопаузальный метаболический синдром и заместительная гормональная терапия. Акушерство и гинекология 2011; 2: 24-31).

10. Zotova IV, Zatejwikov DA, Sidorenko BA. Synthesis of Nitric Oxide and Development of Atherosclerosis. Kardiologiya 2002;42(4): 58-65. Russian (3отова И.В., Затейщиков Д.А., Сидоренко Б.А. Синтез оксида азота и развитие атеросклероза. Кардиология 2002; 42(4): 58-65).

11. Dzerve VYa, Pozdnyakov YuM. Exercise capacity in patients with coronary heart disease and peripheral artery disease, receiving long-term mildronate therapy. Russian Journal of Cardiology 2011;1(87):49-55. Russian (Дзерве, В.Я., Поздняков Ю.М. Динамика толерантности к физической нагрузке у пациентов с ишемической болезнью сердца и периферической болезнью артерий на фоне длительной терапии Милдронатом Российский кардиологический журнал 2011; 1(87): 49-55).

12. Mikhin VP, Pozdnyakov YuM, Khlebodarov FE, Koltsova ON. Mildronate in cardiology practice – current evidence, ongoing research, and future perspectives. Cardiovascular Therapy and Prevention 2012;11(1): 96-103. Russian (Михин В.П., Поздняков Ю.М., Хлебодаров Ф.Е., Кольцова О.Н. Милдронат в кардиологической практике — итоги, новые направления, перспективы. Кардиоваскулярная терапия и профилактика 2012; 11(1): 96-103).

13. Kutishenko NP, Dmitrieva NA, Lukina YV, et al. Кутишенко Н.П. Influence of mildronate on efficiency of antianginal therapy in patients with stable burden angina. Rational Pharmacotherapy in Сardiology 2005;2:37-42. Russian (Кутишенко Н.П., Дмитриева Н.А., Лукина Ю.В. и др. Влияние терапии Милдронатом на эффективность антиангинальной терапии у больных стабильной стенокардией. Рациональная фармакотерапия в кардиологии 2005; 2: 37-42).

14. Perekokin Yu N, Shilo BYu, Gendlin GE. Pulse wave velocity and aortic compliance in patients on maintenance hemodialysis: relationship with risk factors, cardiac calcification and intracardial hemodynamics. Nephrology and Dialysis 2004; 6(1): 36-9. Russian (Перекокин Ю. Н., Шило В. Ю., Гендлин Г. Е. и др. Скорость пульсовой волны и податливость аорты у больных на программном гемодиализе: ее связь с факторами риска, кальцинозом сердца и показателями внутрисердечной гемодинамики. Нефрология и диализ 2004; 6(1): 36-9).

15. Baluda VP, Deyanov II. Determining the value of antithrombogenic properties of the vascular wall in the prevention of thrombosis. Kardiologiya 1988; 28(5):103-5. Russian (Балуда В.П., Деянов И.И. Значение определения антитромбогенных свойств стенки сосудов в профилактике тромбозов. Кардиология 1988; 28(5): 103-5).

16. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part 1: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertension 2005; 23(1): 7-17.

17. Scarda I, Dzerve V, Klincare D, et al. Changes of the patients common state and hemodynamic parameters due to the long-term Mildronate treatment of congestive heart failure. Ist Intern. Meet. «Heart Failure 95»: Abstr. (Apr.1-4 1995, Amsterdam):10.

18. Mikhin VP, Khlebodarov FE. Mildronate potential in patients with cardiovascular disease. Russian Journal of Cardiology 2010;4: 83-92. Russian (Михин В.П., Хлебодаров Ф.Е. Перспективы применения милдроната у больных с сердечно-сосудистой патологией. Российский кардиологический журнал 2010;4: 83-92).

19. Sergienko IV, Kukharchuk VV, Gabrusenko SA. The assessment of effects of combined therapy with mildronate on lipid profile, inflammatory factors and endothelium function in patients with ischemic heart disease. Rational Pharmacotherapy in Сardiology 2007; 3: 10-4. Russian (Сергиенко И.В., Кухарчук В.В., Габрусенко С.А. и др. Оценка влияния комбинированной терапии милдронатом на липидный спектр, факторы воспаления и функцию эндотелия у больных ишемической болезнью сердца. Рациональная фармакотерапия в кардиологии 2007; 3: 10-4).

20. Van Beresteijn ECH, Korevaar JC, Huijbregts PCW. Perimenopausal increase in serum cholesterol: A 10-year longitudinal studi. Am J Epidemiol 1993; 137: 383-92.

21. Protasio Lemos Da Luz, Desiderio Favarato, Jose Rocha Faria-Neto Junior, Pedro Lemos, Antonio Carlos Palandri Chagas. High Ratio of Triglycerides to HDL-Cholesterol Predicts Extensive Coronary Disease. Am J Cardiol 2005;96:1640-3.

22. Gambacciani M, Pepe А. Vasomotor symptoms and cardiovascular risk. Climacteric 2009; (Suppl 1): 32-5.

23. Gerber LM, Sievert LL, Warren K, et al. Hot flushes are associated with increased ambulatory systolic blood pressure. Menopause 2007; 14: 308-15.

24. Gast GC, Samsioe GN, Grobbee DE, et al. Vasomotor symptoms, estradiol levels and cardiovascular risk profile in women. Maturitas 2010; 66: 285- 90.

25. Bystrova MM, Britov AN, Gorbunov VM. HRT in women with hypertension in the peri-and postmenopause: hemodynamic effects. Ter Arkh 2001; 10: 33-8. Russian (Быстрова М.М., Бритов А.Н., Горбунов В.М. и др. ЗГТ у женщин с артериальной гипертонией в пери– и постменопаузе: гемодинамические эффекты. Тер архив 2001; 10: 33-8).

26. Ogata T, Yasaka M, Yamagishi M, et al. Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography. J Ultrasound Med 2005; 24: 469-74.

27. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke:ARIC study. Am J Epidemiol 2000; 151: 478-87.

28. Sergienko IV, Malakhov VV, Naumov VG. Antianginal and antiischemic efficacy mildronate in treatment in patients with coronary artery disease with stable exertional angina. Kardiologiya 2005; 2: 43-5. Russian (Сергиенко И.В., Малахов В.В., Наумов В.Г. Антиангинальная и антиишемическая эффективность милдроната в комплексном лечении у больных ИБС стабильной стенокардией напряжения. Кардиология 2005; 2: 43-5).

29. Khlebodarov FE, Turikov PYu, Mikhin VP. Endothelial dysfunction and its correction wit cytoprotectors in patients with stable effort angina and arterial hypertension. Russian Journal of Cardiology 2009; 6(80): 34-8. Russian (Хлебодаров Ф.Е., Тюриков П.Ю., Михин В.П. Дисфункция сосудистого эндотелия и ее коррекция цитопротекторами у больных стабильной стенокардией напряжения и артериальной гипертонией. Российский кардиологический журнал 2009; 6(80): 34-8).

30. Khebodarov FE, Mikhin VP. Cytoprotector role in the management of arterial hypertension treated with enalapril. Russian Journal of Cardiology 2009; 5: 46-50. Russian (Хлебодаров Ф.Е., Михин В.П. Роль цитопротекторов в лечении больных артериальной гипертонией на фоне терапии эналаприлом. Российский кардиологический журнал 2009; 5: 46-50).

31. Lukyanov MM, Boitsov SA. Arterial wall rigidity as cardiovascular risk and prognostic factor in clinical practice. Serdce 2010; 3(53): 156-9. Russian (Лукьянов М.М., Бойцов С.А. Жесткость артериальной стенки как фактор сердечно-сосудистого риска и прогноза в клинической практике. Сердце 2010; 3(53): 156-9).

32. McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol 2007; 34(7): 665-71.

33. Laurent S, Cockcroft J, Bortel LV, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27(21): 2588-605.

34. Avolio AP, van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension: experts’ Opinion and Review of the Data. Hypertension 2009; 54: 375-83.

35. Wilkinson IB, Mohammad NH, Tyrrell S, et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens 2002; 15: 24-30.

36. Dolan E, Thijs L, Li Y, et al. Ambulatory Arterial Stiffness Index as a Predictor of Cardiovascular Mortality in the Dublin Outcome Study. Hypertension 2006; 47:365-70.

37. Ylikorkala O. Drospirenon-progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms. Climacteric 2005; 8 (suppl): 1-3.

38. Tarasova MA, Jarmolinskaja MI, Solov’eva OA, Sahnovskaja MA. Influence of replaceable therapy 17betta-estradioly in a combination with drospirenony, on dynamics of arterial pressure, endotely-adependent and endotely-independent vasodilatation at women in a postmenopause. Z Acus zen bolezn 2007; V.LVI(2): 3-8. Russian (Тарасова М.А., Ярмолинская М.И., Соловьева О.А., Сахновская М.А. Влияние заместительной терапии 17В-эстрадиолом в сочетании с дроспиреноном на динамику артериального давления, эндотелий -зависимую и эндотелий – независимую вазодилатацию у женщин в постменопаузе. Журнал Акушерства и женских болезней 2007; LVI (2): 3-8.

39. Archer DF, Thorneycroft IH, Foegh M, et al. Efficacy and safety of drospirenone-estradiol for hormone therapy: a double blind, randomized multicenter trial. Menopause 2005; 12(6): 716-27.

40. Mellahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostasis factors according to menopausal status and use of hormone-replacement therapy. Ann Epidemiol 1992; 2: 445-55.